Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: The immunomodulatory drugs thalidomide and lenalidomide recently received US Food and Drug Administration approval for the treatment of multiple myeloma.1-4 Venous thromboembolism (VTE) is a potentially serious complication associated with their use.5-8 We conducted a systematic review of thromboembolism occurring with immunomodulatory drug treatment of cancer.
Methods
We reviewed incidents of thalidomide- or lenalidomide-associated VTE among patients with cancer that were reported to the US Food and Drug Administration's MEDWATCH; reported in phase 2/3 clinical trials presented at hematology/oncology conferences in the United States, Europe, and Australia; or reported as articles published between 1998 and July 2006. Databases searched included PubMed and online abstracts for national and international hematology or oncology conferences. MeSH terms included thalidomide, lenalidomide, deep vein thrombosis, thromboembolism, and pulmonary embolism. The case definition of VTE included deep vein thromboembolism or pulmonary embolism diagnosed with vascular . . . [Full Text of this Article]
Charles L. Bennett, MD, PhD, MPP
cbenne@northwestern.edu
Cara Angelotta, BA
Division of Hematology/Oncology
Paul R. Yarnold, PhD
Department of Emergency Medicine
Andrew M. Evens, DO, MS
Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Ill
Jeffrey A. Zonder, MD
Division of Hematology-Oncology
Karmanos Cancer Institute
Wayne State University
Detroit, Mich
Dennis W. Raisch, PhD
VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center
University of New Mexico
Albuquerque
Paul Richardson, MD
Division of Hematologic Malignancy
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Mass
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cancer and thrombosis: implications of published guidelines for clinical practice
Khorana
Ann Oncol 2009;20:1619-1630.
ABSTRACT
| FULL TEXT
Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
Lee et al.
JNCI J Natl Cancer Inst 2009;101:1049-1057.
ABSTRACT
| FULL TEXT
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Richardson et al.
Blood 2009;114:772-778.
ABSTRACT
| FULL TEXT
Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
Richardson et al.
JCO 2009;27:3518-3525.
ABSTRACT
| FULL TEXT
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
Johnson et al.
Blood 2008;112:4924-4934.
ABSTRACT
| FULL TEXT
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-analysis
Nalluri et al.
JAMA 2008;300:2277-2285.
ABSTRACT
| FULL TEXT
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
Kristinsson et al.
Blood 2008;112:3582-3586.
ABSTRACT
| FULL TEXT
Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma
Lacy et al.
Mayo Clin Proc. 2007;82:1179-1184.
ABSTRACT
| FULL TEXT
Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers
Bennett et al.
Arch Intern Med 2007;167:1041-1049.
ABSTRACT
| FULL TEXT
|
